We’re excited to attend the BVS EMD Serono Research & Development Institute Biotech Community Expo on May 6th in Billerica, MA. EMD Serono is a healthcare company of Merck KGaA with a focus on transformative research within immunology, neurology and oncology. This is an exclusive opportunity to network and collaborate with industry experts, come meet the Biocytogen team and learn more about our innovative technologies!
What is the BVS?
Founded in 2003, Biotech Vendor Services (BVS) is a vendor neutral organization that hosts showcases, summits, and seminars with the goal of connecting scientists and suppliers. Their customized events provide a stimulating platform for attendees to exchange the latest discoveries and form meaningful connections.
Event Overview
Date: May 6th, 2026
Venue: EMD Serono, 45 Middlesex Turnpike, Billerica, MA 01821
Event Schedule
For more information about BVS, please visit their website here.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to forming long lasting partnerships and driving the future of life sciences together!
